Blood: Will Bruton tyrosine kinase inhibitors affect the effectiveness of vaccination?

Vaccines are effective in preventing infection; there is good news coming from the development of new crown vaccines, which are now getting closer to mass vaccination.
, however, it is not clear whether patients with chronic lymphoblastic leukemia (CLL) who are not treated (TN) or treated with Bruton tyrosine kinase inhibitors (BTKis) are responding to the new ad ligation vaccine.
Given the widespread use of BTKis and the need for new coronary pneumonia vaccines to prevent new coronavirus infections, there is an urgent need to clarify the impact of BTKis on body fluids immunization before mass vaccination of new coronavirus.
In two open-labeled one-arm clinical trials, Christopher and others tested the role of BTKis' head-to-head immune response to recombined hepatitis B vaccine (HepB-CpG) and reimmune response to recombined shingles vaccine (RZV) in CLL patients.
main endpoints are serological responses to HepB-CpG (anti-HBs≥10mIU/mL) and RZV (anti-glycoprotein E increase ≥4x).
patients treated with BTKi had a lower response rate to HepB-CpG than TN patients (3.8% (95% CI, 0.7% to 18.9%) vs 28.1% (95% CI, 15.6% to 45.4%) and P .017).
contrast, there was no significant difference in RZV response rates between the BTKi and TN groups (41.5% (95% CI, 27.8% to 56.6%) vs 59.1% (95% CI, 38.7% to 76.7 percent), P=0.2).
, BTKis therapy may weaken the effect of the head-on immune response after hepB-CpG vaccination, while BTKi therapy has no significant effect on the reimmune response after RZV.
this shows that BTKis have different effects on different vaccines, so we need specific trials to see if BTKis will affect the effectiveness of the new crown vaccine, not simply from other vaccines.
。